Glycopyrrolate inhalation - Novartis

Drug Profile

Glycopyrrolate inhalation - Novartis

Alternative Names: AD-237; Enurev Breezhaler; Inhaled glycopyrrolate; Inhaled glycopyrronium bromide; NVA-237; Seebri Breezhaler; Seebri Inhalation Capsules; Seebri Neohaler; Tovanor Breezhaler

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Arakis Ltd; Vectura
  • Developer Novartis
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 12 Apr 2017 Phase-II clinical trials in Asthma (Adjunctive treatment) in Germany (Inhalation) (EudraCT2015-005565-23)
  • 03 Apr 2017 Sunovion Pharmaceuticals expects to launch glycopyrrolate (Seebri™) in the US by the end of 2017
  • 21 Dec 2016 Glycopyrrolate inhalation licensed to Sunovion Pharmaceuticals in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top